Literature DB >> 18269491

Analysing clinical studies: principles, practice and pitfalls of Kaplan-Meier plots.

John Ludbrook1, Alistair G Royse.   

Abstract

THE PROBLEM: The conventional method for estimating survival over time following an episode of disease or treatment is the Kaplan-Meier (K-M) technique, which results in a step-down survival plot, with upper and lower bounds of 1.0 and 0, respectively. The mirror image of this plot represents the cumulative incidence of an adverse event, such as death, with lower and upper bounds of 0 and 1.0, respectively. However, if there are two competing events that can occur during follow up, such as death or relapse, the K-M technique gives a false picture of the cumulative incidence of either one of these events. This occurs because patients who have died cannot subsequently relapse. THE SOLUTION: When there are two competing events, another technique must be used, which is known, variously, as cumulative incidence analysis, or 'actual' (as opposed to actuarial) incidence analysis. An example is given in which there are two competing adverse events following haemopoietic stem cell transplantation for a haematological malignancy: (i) relapse or (ii) transplant-related death. Our analysis of the example shows that the cumulative probability of relapse is progressively inflated if the traditional K-M product-limit method is used rather than actual cumulative incidence analysis. We show how K-M and actual cumulative survival or incidence analyses can be executed by a handheld calculator for small datasets or by formulae within a computer spreadsheet for large datasets.
CONCLUSIONS: Surgical investigators should not use the K-M technique to predict cumulative survival or risk if there are two competing adverse events. They should use, instead, the technique of actual cumulative survival or incidence analysis.

Entities:  

Mesh:

Year:  2008        PMID: 18269491     DOI: 10.1111/j.1445-2197.2007.04405.x

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  8 in total

1.  Long-term results of palliative stent placement for acute malignant colonic obstruction.

Authors:  M W van den Berg; M Ledeboer; M G W Dijkgraaf; P Fockens; F ter Borg; J E van Hooft
Journal:  Surg Endosc       Date:  2014-10-08       Impact factor: 4.584

2.  Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006.

Authors:  D P Cronin-Fenton; F Søndergaard; L A Pedersen; J P Fryzek; K Cetin; J Acquavella; J A Baron; H T Sørensen
Journal:  Br J Cancer       Date:  2010-09-14       Impact factor: 7.640

3.  Web-based tools for microRNAs involved in human cancer.

Authors:  Fermín Mar-Aguilar; Cristina Rodríguez-Padilla; Diana Reséndez-Pérez
Journal:  Oncol Lett       Date:  2016-04-18       Impact factor: 2.967

4.  Paraneoplastic antigen Ma2 autoantibodies as specific blood biomarkers for detection of early recurrence of small intestine neuroendocrine tumors.

Authors:  Tao Cui; Monica Hurtig; Graciela Elgue; Su-Chen Li; Giulia Veronesi; Ahmed Essaghir; Jean-Baptiste Demoulin; Giuseppe Pelosi; Mohammad Alimohammadi; Kjell Öberg; Valeria Giandomenico
Journal:  PLoS One       Date:  2010-12-30       Impact factor: 3.240

5.  Clinical outcomes of surgical management for recurrent rectal prolapse: a multicenter retrospective study.

Authors:  Kwang Dae Hong; Keehoon Hyun; Jun Won Um; Seo-Gue Yoon; Do Yeon Hwang; Jaewon Shin; Dooseok Lee; Se-Jin Baek; Sanghee Kang; Byung Wook Min; Kyu Joo Park; Seung-Bum Ryoo; Heung-Kwon Oh; Min Hyun Kim; Choon Sik Chung; Yong Geul Joh
Journal:  Ann Surg Treat Res       Date:  2022-04-05       Impact factor: 1.766

6.  Competing-risks nomogram for predicting cancer-specific death in upper tract urothelial carcinoma: a population-based analysis.

Authors:  Chengzhuo Li; Didi Han; Qiao Huang; Fengshuo Xu; Shuai Zheng; Xiang Li; Fanfan Zhao; Xiaojie Feng; Jun Lyu
Journal:  BMJ Open       Date:  2021-07-19       Impact factor: 2.692

7.  Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease.

Authors:  Laura van Dussen; Marieke Biegstraaten; Carla E M Hollak; Marcel G W Dijkgraaf
Journal:  Orphanet J Rare Dis       Date:  2014-04-14       Impact factor: 4.123

8.  Modelling Gaucher disease progression: long-term enzyme replacement therapy reduces the incidence of splenectomy and bone complications.

Authors:  Laura van Dussen; Marieke Biegstraaten; Marcel Gw Dijkgraaf; Carla Em Hollak
Journal:  Orphanet J Rare Dis       Date:  2014-07-24       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.